Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy. Ariel Lopez-Chavez, MD, ...

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with ...

Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the ...

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic ...